New progestins and potential actions

Area of Science:

• Pharmacology
• Endocrinology
• Molecular Biology

Background:

• Development of novel progestins is crucial for targeted therapies.
• Existing progestins may have undesirable side effects or lack tissue selectivity.

Purpose of the Study:

• To describe the development of newer, nonsteroidal, orally active, tissue-selective progestins.
• To outline the molecular approach utilizing the human progesterone receptor (hPR) as the target.
• To define the desirable characteristics of next-generation progestin compounds.

Main Methods:

• Molecular approach for compound selection targeting the human progesterone receptor (hPR).
• Co-transfection and binding assays to assess receptor selectivity and cross-reactivity.
• Analysis of transcriptional products to profile new progestin compounds.

Main Results:

• New progestins are being developed with a focus on hPR as the molecular target.
• Assays are employed to ensure selectivity and minimize off-target effects.
• Compounds are profiled for specific desirable characteristics.

Conclusions:

• Newer progestins are under development with a molecular-driven, tissue-selective approach.
• These compounds aim to possess beneficial properties such as suppressing endometrial stimulation and maintaining pregnancy.
• The goal is to achieve efficacy with minimal adverse physiological effects.